Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28019652 | 1.00 | LIPE (0.44) | LIPEFAAHPHGDHMGLLALDH1A1 | |
| SCHEMBL15551380 | 1.00 | LIPE (0.44) | LIPEFAAHPHGDHMGLLALDH1A1 | |
| SCHEMBL31097151 | 0.94 | HPGD (0.43) | LIPEALDH1A1HPGDHTTHSD11B1 | |
| SCHEMBL1561215 | 0.87 | LMNA (0.49) | LIPEFAAHPHGDHMGLLALDH1A1 | |
| SCHEMBL28960167 | 0.85 | CA2 (0.44) | LIPEHPGDHSD11B1HSD11B2KMT2A | |
| SCHEMBL30967383 | 0.85 | CA2 (0.44) | LIPEFAAHPHGDHMGLLALDH1A1 | |
| SCHEMBL4375383 | 0.85 | MAPT (0.50) | LIPEALDH1A1PKMHTTKMT2A | |
| SCHEMBL30967349 | 0.83 | CHRNB2 (0.44) | LIPEFAAHPHGDHMGLLALDH1A1 | |
| SCHEMBL19001142 | 0.83 | LIPE (0.39) | LIPEFAAHPHGDHMGLLALDH1A1 | |
| SCHEMBL30967375 | 0.81 | CHRNB2 (0.46) | LIPEALDH1A1PKMHSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185817-A1 | IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185817-A1 | IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK1 | LIPE 4272/4885FAAH 4350/4885PHGDH 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.